Key Drivers
- Strong cash conversion
- Moderate leverage
- Intangible-heavy assets
AIAI Summary
ZBH now looks more like a credible near-term momentum story than a slow-growth medical device laggard thanks to improving sales, raised guidance, and strong cash flow, but flat adjusted EPS, meaningful leverage, and a rich valuation mean the stock is best viewed as a solid cash generator with limited margin for error rather than a high-conviction re-rating candidate.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash conversion
- •Moderate leverage
- •Intangible-heavy assets
ZBH is a steady cash-generating medtech name with strong margins and FCF, but modest returns, moderate leverage, heavy intangibles, and a rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Shallow pullbacks
- •Near resistance
ZBH has trended higher over the last month with buyers repeatedly defending the $97–$98 area and stronger support near $95.80, but it is now stretched near resistance at $100.65 and may pause unless it breaks higher.
Quick rally has left the stock stretched near the top of its recent range
Sentiment & News
Key News Insights:
- •Guidance Raised
- •Broad Sales Growth
- •Margin Pressure
Zimmer Biomet beat Q2 expectations, raised full-year guidance, and showed broad sales improvement in hips, specialty, and technology despite some margin pressure.
The stronger-than-expected quarter and improved outlook should support ZBH sentiment, though margin pressure may cap near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings